SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Fredun Pharmaceuticals informs about outcome of board meeting

28 Jan 2023 Evaluate

Fredun Pharmaceuticals has informed that the Board of Directors of the company, at their Meeting held on Friday, 27th January, 2023 had considered and approved the following item: In compliance to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Un-Audited Financial Results of the Company for the quarter ended 31st December 2022 along with the Limited Review Report as issued by Savla & Associates, Statutory Auditors of the Company; copies of which are attached. The Meeting of the Board Commenced at 2.00 pm and concluded at 08:00 pm.

The above information is a part of company’s filings submitted to BSE.

Fredun Pharma Share Price

2043.90 -23.80 (-1.15%)
21-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1665.25
Dr. Reddys Lab 1220.75
Cipla 1232.90
Zydus Lifesciences 928.85
Lupin 2311.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×